European Commission authorizes subcutaneous Ocrevus for multiple sclerosis

The European Commission has authorized a subcutaneous injection of Ocrevus to treat relapsing multiple sclerosis as well as primary progressive MS, according to the manufacturer.

The subcutaneous formulation of Ocrevus (ocrelizumab) is a 10-minute, twice-a-year injection designed to be administered by health care providers either inside or outside the clinical setting. Its safety and efficacy profile, as shown in the phase 3 OCARINA II clinical trial, was similar to the previously approved IV infusion in patients with both relapsing and primary progressive MS, Roche said in a press release.

According to statistics cited in the release, more than 92% of surveyed participants reported being satisfied or very satisfied with subcutaneous administration of the humanized, monoclonal antibody which targets CD20-positive B cells.

“Ocrevus transformed the way multiple sclerosis is treated as the first anti-CD20 therapy approved in this disease. Now, people in the [European Union] with multiple sclerosis can have their medicine administered in just 10 minutes twice per year without needing an IV facility,” Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development for Roche, said in the release. “This makes it easier for more people with multiple sclerosis to access their treatment, while also saving time for providers.”